I don't think so. My thought on this stock for a while now has been that the majority of folks who want in at this level, before news that seriously impacts risk (positively or negatively), are already in. And conversely, the majority of those who don't want in right now, aren't. Shares just aren't trading on any consequential level. And honestly, the news that has come out hasn't been impactful enough to change most investors' paradigms or thought processes. I think they're just feeding shareholders a few PR's to keep them in the loop, since most were expecting PE's from combo by now. I think you'll see significant movement in share price when they release combo PE's, one way or another.
Plus, as has been referenced more times than I can count, of course they're going to raise money in the future. They're a clinical stage, pre-revenue biotech. That's how they fund operations. And of course they're trying to do it at a better share price based on exciting news. The only way that doesn't happen is if they sell or partner pretty much immediately. If anyone is taken aback by the prospect that the firm may be trying to use exciting news to raise money, they're probably chasing the wrong tail to begin with.
News 
Market Data 
Discover 
